Qurexa Logo
Qurexa

Trust. Care. Deliver.

Back to Blog & Insights
Health

A daily liquid, a carefully controlled diet, and a UK approval that comes with conditions

Qurexa Editorial Team31 October 20268 min read 0 0
A daily liquid, a carefully controlled diet, and a UK approval that comes with conditions

What happened

On 30 October 2026, the MHRA approved a medicine called triheptanoin, sold as Dojolvi, for adults and children with a group of rare inherited conditions known as long-chain fatty acid oxidation disorders. These are usually shortened to LC-FAOD. The medicine is an oral liquid. That means it is swallowed rather than injected. It is taken every day, and it has to be used as part of a carefully controlled diet. The approval is conditional. This is an important detail. The MHRA says more evidence on how well the medicine works and how safe it is, from an ongoing study in children, is still needed before a full marketing authorisation can be granted. The marketing authorisation was granted to Ultragenyx Netherlands. Triheptanoin is available on prescription only. Julian Beach, the MHRA's Executive Director of Operations, said that enabling patient access to high quality, safe and effective medical products is important to the agency. He also said that patients with rare diseases often face significant barriers to effective treatments, and that the appropriate regulatory standards for this approval were met. He added: 'As with all products, we will keep the safety of triheptanoin under close review.' As with other new approvals, the MHRA said the full prescribing document and the patient information leaflet would appear on its Products website within seven days.

Why this matters

Most of us never think about how our bodies turn food into energy. It simply happens. For people with LC-FAOD, part of that process does not work. The MHRA explains it like this: people with these conditions cannot use long-chain fatty acids as a source of energy. Fatty acids are one of the main fuels the body relies on, especially when you have not eaten for a while, when you are ill, or when you are exercising hard. If the body cannot use them, it can struggle to make enough energy. The consequence is not vague tiredness. The MHRA says it puts people at risk of serious clinical events that often lead to frequent hospital stays. The agency also sets out what can go wrong inside cells during an energy crisis: muscle breakdown, damage to the heart muscle, and low blood sugar. That is why a medicine like this matters out of proportion to the number of people who need it. LC-FAOD affects people of all ages, and for families living with it, the aim is not simply comfort. It is avoiding emergencies. There is a second reason this decision is worth noticing. Rare conditions, by definition, affect small numbers of people. That makes it harder to run large trials, harder to attract investment, and harder for regulators to reach the level of certainty they would have for a common illness. Conditional approval is one of the tools regulators use to let patients get access while evidence keeps being collected. It is a deliberate trade-off, and it is honest about being one.

What the evidence actually says

Let us be precise about what is known publicly and what is not. The MHRA's announcement did not publish trial results, participant numbers, or detailed figures on how well the medicine works. So nobody reading the press release can say 'it reduced hospital stays by X per cent'. If you see a figure like that, check where it came from. What the MHRA did publish is how the medicine is meant to work. Triheptanoin is a medium-chain triglyceride. In plain terms, it supplies a different kind of fat that the body can break down without needing the enzymes that are missing or faulty in LC-FAOD. The MHRA says it helps prevent energy crises in cells, which can otherwise cause muscle breakdown, heart muscle damage and low blood sugar. On side effects, the MHRA is specific. The most common ones, which may affect more than one in ten people, are stomach pain, diarrhoea and vomiting. More than one in ten is common, not rare, so this is worth knowing before starting. The agency says suspected side effects should be reported to a doctor, pharmacist or nurse, or directly through the Yellow Card scheme. The conditional nature of the approval is the clearest statement of uncertainty available. The MHRA is saying, in effect: the evidence met the standard required for this kind of authorisation, and we expect more of it from an ongoing study in children. One piece of useful context: this is not the first country to approve triheptanoin for this use. The United States regulator approved it for long-chain fatty acid oxidation disorders in June 2020. That does not make the UK decision automatic, because each regulator assesses the evidence itself, but it does mean there is real-world experience elsewhere.

Qurexa perspective

This is a medicine that only works if it is actually taken, every day, alongside a diet that has been carefully worked out. That is a demanding routine, and it is the kind of routine where small practical problems cause real harm. At Qurexa, our work across Lincolnshire is prescription delivery and medication adherence support, so this pattern is familiar to us. The medicines that cause the most trouble are rarely the complicated ones. They are the ones where the supply runs out on a Friday, or where a repeat prescription was not reordered in time because the person was unwell that week - which is exactly when they need it most. For a condition where missing fuel can trigger an emergency, running out is not an inconvenience. So if you or someone you care for is prescribed a daily liquid medicine, it is worth building a routine that does not depend on remembering: a reorder date in the calendar a week before you run out, a named person who checks, and a plan for what to do if a supply problem appears. We would add one honest note. Triheptanoin is a specialist medicine for a rare condition, and it will be managed by a specialist metabolic team. It is not something a community delivery service decides anything about. Our point is narrower: whoever supplies your medicines, make sure the practical side is nailed down, because that is where avoidable problems happen.

Practical advice

If this approval is relevant to you or your family, here is what is worth doing. **Speak to your metabolic or specialist team.** LC-FAOD is managed by specialists. They are the only people who can say whether this medicine is suitable for a particular person, and how it would fit with the diet already in place. **Do not change your diet on your own.** The MHRA is clear that this medicine is used as part of a carefully controlled diet. Changing what you eat without your dietitian's input could undo the point of the treatment. **Follow the directions exactly.** The MHRA says the medicine is prescription-only and that patients should follow their healthcare professional's directions precisely. With a liquid, that means measuring properly, using the device you were given rather than a kitchen spoon. **Expect the common side effects and talk about them.** Stomach pain, diarrhoea and vomiting may affect more than one in ten people. If they happen, tell your team rather than quietly stopping. There may be ways to manage them. **Read the leaflet when it appears.** The MHRA said the Summary of Product Characteristics and patient information leaflet would be on its Products website within seven days of approval. The leaflet is written for patients and is more useful than most people expect. **Use the Yellow Card scheme.** If you think a medicine has caused a side effect, report it. For a medicine with a conditional approval, this kind of real-world reporting genuinely feeds into what regulators learn next.

What to know

The MHRA has conditionally approved triheptanoin (Dojolvi) for adults and children with long-chain fatty acid oxidation disorders, a group of rare inherited conditions. The announcement was made on 30 October 2026, and the authorisation went to Ultragenyx Netherlands. People with LC-FAOD cannot use long-chain fatty acids for energy, which puts them at risk of serious events and frequent hospital stays. The medicine supplies fats the body can use instead, helping prevent energy crises in cells that can lead to muscle breakdown, heart muscle damage and low blood sugar. It is a liquid taken daily by mouth, on prescription only, as part of a carefully controlled diet. The most common side effects, affecting possibly more than one in ten people, are stomach pain, diarrhoea and vomiting. The approval is conditional: more evidence from an ongoing study in children is needed before a full authorisation. The MHRA says it will keep the medicine's safety under close review. The same medicine has been approved for this use in the United States since June 2020. Sources: GOV.UK (MHRA), 'Triheptanoin (Dojolvi) approved to treat adults and children with a group of rare inherited disorders', 30 October 2026, https://www.gov.uk/government/news/triheptanoin-dojolvi-approved-to-treat-adults-and-children-with-a-group-of-rare-inherited-disorders; US Food and Drug Administration, Dojolvi (triheptanoin) approval package, 30 June 2020, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213687Orig1s000Approv.pdf; GOV.UK, Medicines and Healthcare products Regulatory Agency, accessed 31 October 2026, https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency This article is for general information and does not replace advice from a doctor, pharmacist, dietitian or other qualified healthcare professional. Never start, stop or change a prescribed medicine or a prescribed diet without speaking to your specialist team.

#rare diseases#MHRA#medicines approval#metabolic conditions#prescriptions#patient safety

Related articles